Ecnoglutide: read the trial behind the claim

PRIMARY EVIDENCE CHECKED NOVEMBER 12, 2026

Ecnoglutide is described in primary publications as a cAMP-biased GLP-1 receptor agonist. The studies below examine weight management or glucose control; they are not interchangeable evidence for every use. A published trial also does not by itself establish regulatory approval in a jurisdiction.

Weight management: the 2025 phase 3 study

A randomized, double-blind, placebo-controlled study enrolled 664 adults with overweight or obesity in China. Participants received one of three ecnoglutide groups or placebo. The treatment period was 48 weeks. The original report and registration are the right place to check analysis definitions and adverse events before reusing a headline. Primary publication, PMID 40555243; NCT05813795.

Glucose control: EECOH-1

EECOH-1 studied monotherapy in adults with type 2 diabetes. Its 24-week double-blind comparison involved 211 randomized participants and placebo controls, followed by an open-label period. This is a different population and question from the obesity study. Primary report; NCT05680155.

Active comparison: EECOH-2

EECOH-2 was a 52-week, open-label, randomized phase 3 non-inferiority comparison with dulaglutide in people with type 2 diabetes and elevated glucose on metformin. The active comparator and non-inferiority question distinguish it from a placebo-controlled obesity trial. Primary publication, PMID 40854315.

A practical evidence checklist

1. Population: Does the claim concern people with diabetes, people without diabetes, or a specified subgroup?
2. Comparator: Was treatment compared with placebo or another drug? Was the trial blinded?
3. Question: Was the endpoint body weight, glycemic control, or something else?
4. Analysis: Does the number describe everyone randomized, participants staying on treatment, or another defined analysis?
5. Scope: Does the source support the exact claim, or only a narrower one?

Read a trial’s limitations and safety reporting alongside its efficacy endpoints. Cross-trial differences do not create a randomized head-to-head comparison. This selected evidence note makes no current worldwide approval, availability or treatment-selection claim.